CY1121309T1 - Μμρ ενεργοποιουμενοι παραγοντες αγγειακης διαρρηξης - Google Patents
Μμρ ενεργοποιουμενοι παραγοντες αγγειακης διαρρηξηςInfo
- Publication number
- CY1121309T1 CY1121309T1 CY20191100241T CY191100241T CY1121309T1 CY 1121309 T1 CY1121309 T1 CY 1121309T1 CY 20191100241 T CY20191100241 T CY 20191100241T CY 191100241 T CY191100241 T CY 191100241T CY 1121309 T1 CY1121309 T1 CY 1121309T1
- Authority
- CY
- Cyprus
- Prior art keywords
- vascular
- breaking
- activating factors
- mmp
- mmp activating
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title 1
- 230000002792 vascular Effects 0.000 title 1
- 206010053649 Vascular rupture Diseases 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000006337 proteolytic cleavage Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0819287.4A GB0819287D0 (en) | 2008-10-22 | 2008-10-22 | Compounds |
| PCT/GB2009/002484 WO2010046628A1 (en) | 2008-10-22 | 2009-10-20 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121309T1 true CY1121309T1 (el) | 2020-05-29 |
Family
ID=40097772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100241T CY1121309T1 (el) | 2008-10-22 | 2019-02-27 | Μμρ ενεργοποιουμενοι παραγοντες αγγειακης διαρρηξης |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US8927486B2 (enExample) |
| EP (2) | EP3446715A1 (enExample) |
| JP (1) | JP5820272B2 (enExample) |
| CN (2) | CN102143762B (enExample) |
| CA (1) | CA2741475A1 (enExample) |
| CY (1) | CY1121309T1 (enExample) |
| DK (1) | DK2349344T5 (enExample) |
| ES (1) | ES2714590T3 (enExample) |
| GB (1) | GB0819287D0 (enExample) |
| HR (1) | HRP20190437T8 (enExample) |
| HU (1) | HUE042688T2 (enExample) |
| LT (1) | LT2349344T (enExample) |
| PL (1) | PL2349344T3 (enExample) |
| PT (1) | PT2349344T (enExample) |
| SI (1) | SI2349344T1 (enExample) |
| SM (1) | SMT201900127T1 (enExample) |
| TR (1) | TR201902884T4 (enExample) |
| WO (1) | WO2010046628A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0707034D0 (en) | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| JP6356684B2 (ja) | 2012-11-02 | 2018-07-11 | マレイ・アンド・プール・エンタープライゼズ・リミテッド | コルヒチン誘導体の投与による心血管イベントの処置または予防 |
| EA037375B1 (ru) | 2013-04-16 | 2021-03-22 | Марри Энд Пул Энтерпрайзес Лимитед | Составы с замедленным высвобождением, содержащие колхицин, и способы их применения |
| GB2516882A (en) * | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| EP4176896B1 (en) | 2014-01-31 | 2025-10-08 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| GB2545169B (en) * | 2015-12-01 | 2019-10-09 | Ellipses Pharma Ltd | Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| CN115353534B (zh) * | 2021-12-31 | 2024-06-07 | 郑州大学第一附属医院 | 一种秋水仙碱衍生物及其制备和其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US819287A (en) * | 1905-09-11 | 1906-05-01 | Caesar Klaus | Automatic brake. |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6844318B2 (en) * | 2000-03-15 | 2005-01-18 | Bristol Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| GB0018240D0 (en) | 2000-07-25 | 2000-09-13 | Pharmacia & Upjohn Spa | Polymeric conjugates of antitumor agents |
| GB0105929D0 (en) | 2001-03-09 | 2001-04-25 | Btg Int Ltd | Physiologically activated prodrugs |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| GB0320691D0 (en) * | 2003-09-04 | 2003-10-01 | Smith & Nephew | Use of joint lining cells for articular cartilage repair |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| CN101146826A (zh) | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| WO2006090813A1 (ja) | 2005-02-25 | 2006-08-31 | National University Corporation Hokkaido University | 腫瘍組織で選択的に分解性を示す血中滞留性素子 |
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| GB0707034D0 (en) | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
-
2008
- 2008-10-22 GB GBGB0819287.4A patent/GB0819287D0/en not_active Ceased
-
2009
- 2009-10-20 LT LTEP09760548.9T patent/LT2349344T/lt unknown
- 2009-10-20 PL PL09760548T patent/PL2349344T3/pl unknown
- 2009-10-20 HU HUE09760548A patent/HUE042688T2/hu unknown
- 2009-10-20 WO PCT/GB2009/002484 patent/WO2010046628A1/en not_active Ceased
- 2009-10-20 JP JP2011532704A patent/JP5820272B2/ja not_active Expired - Fee Related
- 2009-10-20 CA CA2741475A patent/CA2741475A1/en not_active Abandoned
- 2009-10-20 TR TR2019/02884T patent/TR201902884T4/tr unknown
- 2009-10-20 CN CN200980141703.3A patent/CN102143762B/zh not_active Expired - Fee Related
- 2009-10-20 EP EP18194638.5A patent/EP3446715A1/en not_active Withdrawn
- 2009-10-20 DK DK09760548.9T patent/DK2349344T5/en active
- 2009-10-20 EP EP09760548.9A patent/EP2349344B1/en active Active
- 2009-10-20 HR HRP20190437TT patent/HRP20190437T8/hr unknown
- 2009-10-20 SI SI200931938T patent/SI2349344T1/sl unknown
- 2009-10-20 CN CN201410401756.7A patent/CN104193802B/zh not_active Expired - Fee Related
- 2009-10-20 ES ES09760548T patent/ES2714590T3/es active Active
- 2009-10-20 PT PT09760548T patent/PT2349344T/pt unknown
- 2009-10-20 SM SM20190127T patent/SMT201900127T1/it unknown
- 2009-10-20 US US13/125,732 patent/US8927486B2/en not_active Expired - Fee Related
-
2014
- 2014-11-25 US US14/553,803 patent/US20150196658A1/en not_active Abandoned
-
2016
- 2016-10-19 US US15/297,649 patent/US9937267B2/en active Active
-
2018
- 2018-03-01 US US15/909,475 patent/US10912839B2/en not_active Expired - Fee Related
-
2019
- 2019-02-27 CY CY20191100241T patent/CY1121309T1/el unknown
-
2020
- 2020-06-19 US US16/946,391 patent/US20200316212A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180177886A1 (en) | 2018-06-28 |
| EP2349344A1 (en) | 2011-08-03 |
| US20200316212A1 (en) | 2020-10-08 |
| HK1204792A1 (en) | 2015-12-04 |
| CN102143762A (zh) | 2011-08-03 |
| DK2349344T3 (en) | 2019-03-25 |
| US9937267B2 (en) | 2018-04-10 |
| LT2349344T (lt) | 2019-03-25 |
| US20110275554A1 (en) | 2011-11-10 |
| US20170266307A1 (en) | 2017-09-21 |
| HUE042688T2 (hu) | 2019-07-29 |
| DK2349344T5 (en) | 2019-04-01 |
| EP3446715A1 (en) | 2019-02-27 |
| JP2012506408A (ja) | 2012-03-15 |
| CN102143762B (zh) | 2014-10-22 |
| US10912839B2 (en) | 2021-02-09 |
| PT2349344T (pt) | 2019-03-21 |
| PL2349344T3 (pl) | 2019-11-29 |
| EP2349344B1 (en) | 2018-12-05 |
| GB0819287D0 (en) | 2008-11-26 |
| SI2349344T1 (sl) | 2019-04-30 |
| US20150196658A1 (en) | 2015-07-16 |
| WO2010046628A1 (en) | 2010-04-29 |
| CN104193802A (zh) | 2014-12-10 |
| TR201902884T4 (tr) | 2019-03-21 |
| US8927486B2 (en) | 2015-01-06 |
| JP5820272B2 (ja) | 2015-11-24 |
| ES2714590T3 (es) | 2019-05-29 |
| CN104193802B (zh) | 2020-03-24 |
| HRP20190437T1 (hr) | 2019-04-19 |
| HRP20190437T8 (hr) | 2019-06-14 |
| SMT201900127T1 (it) | 2019-05-10 |
| CA2741475A1 (en) | 2010-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121309T1 (el) | Μμρ ενεργοποιουμενοι παραγοντες αγγειακης διαρρηξης | |
| CY1124103T1 (el) | Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης | |
| CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
| BR112012008538A2 (pt) | modulação energética de nervos | |
| CR11299A (es) | Amidas heterociclicas utiles para el tratamiento de cancer y psoriasis | |
| DE602007000323D1 (de) | Abgabe von therapeutischen Vorrichtungen | |
| HN2011003139A (es) | Antagonistas de trayectoria de erizo de ftalazina disustituida | |
| CY1116435T1 (el) | Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων | |
| CL2012000063A1 (es) | Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07). | |
| CY1119030T1 (el) | Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων | |
| CY1112259T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας | |
| CY1108748T1 (el) | Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων | |
| MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
| EP2052011A4 (en) | GUARANTEED POLYLYSINDENDRIMER THERAPEUTIC | |
| CR20120508A (es) | PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES | |
| CY1114960T1 (el) | Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου | |
| CY1113102T1 (el) | Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων | |
| CR20120008A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CY1116840T1 (el) | Χρηση 24-norudca | |
| CY1114023T1 (el) | Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog | |
| ECSP12012315A (es) | FACTOR VIIa CONJUGADO PARA COAGULACIÓN DE LA SANGRE | |
| ATE334705T1 (de) | Enzymabhängige therapeutische wundverbände | |
| BRPI0906608A2 (pt) | Métodos e composições para o tratamento de hemorragia subaracnóide aneurismal coronária e arterial. | |
| CY1109733T1 (el) | Χρησιμοποιηση πολυαιθυλενο γλυκολης για τη θεραπεια παθησεων ασθενειων και τραυματων, που εχουν σχεση με φλεγμονη | |
| CY1120368T1 (el) | Αλληλουχια ειδικης διασπασης μμρ-14 |